US payer budget impact of a microarray assay with machine learning to evaluate kidney transplant rejection in for-cause biopsies
US payer budget impact of a microarray assay with machine learning to evaluate kidney transplant rejection in for-cause biopsies
Dr. Chris Lawrence explores how a US payer budget model demonstrates that MMDx® Kidney is a cost-effective intervention despite the cost of the assay and the higher treatment costs associated with identifying more rejection.

Added Date:

2022-05-20

Filters:

Filter Category Filter Values
Resource Type
  • Publication Summary
Keywords
  • TCMR
  • DSA
  • MMDx
Products and Services
  • MMDx
Scope Filters
  • MMDx Resources
  • Scientific Research
Areas of Interest
  • DSA
  • TCMR
  • Biopsy Assessment

Country Availability:


()

Gated Form:

None Set